Business & Commerce

#52026M12363Prior Notification of GBL and CVC Joint Acquisition of Rayner

🇪🇺European Union··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

The law involves a proposed joint acquisition where Groupe Bruxelles Lambert and CVC Capital Partners will gain control of UK-based Rayner Surgical Group. This change primarily impacts stakeholders in the ophthalmic surgical products market as Rayner is a key player in this sector. The European Commission invites third parties to submit observations on this acquisition, which could be treated under a simplified procedure due to its scope.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • GBL and CVC's joint control acquisition of Rayner Surgical Group
  • Potential treatment under EU's simplified merger procedure
  • Opportunity for third parties to submit observations

Obligations

What this law requires

medium

Interested third parties must submit their observations on the proposed concentration to the Commission.

third parties
10 days following the date of publication
reporting
medium

Interested third parties must submit observations on the proposed concentration to the Commission.

third parties
10 days after the publication date
reporting
medium

Observations must reference 'M. 12363 – GBL / CVC / RAYNER' when submitted.

third parties
disclosure
medium

Observations must specify the reference: M. 12363 – GBL / CVC / RAYNER.

third parties
10 days after the publication date
reporting
low

Observations can be submitted via email or post to the specified contact details.

third parties
reporting

Affected Parties

Groupe Bruxelles Lambert SACVC Capital Partners

Tags

mergers,ophthalmic devices,competition